J. Tiercy, How to select the best available related or unrelated donor of hematopoietic stem cells?, Haematologica, vol.101, pp.680-687, 2016.

L. Gragert, HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry, N. Engl. J. Med, vol.371, pp.339-348, 2014.

V. Gupta, Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis, Blood, vol.116, pp.1839-1848, 2010.

W. Saber, Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia, Blood, vol.119, pp.3908-3916, 2012.

R. F. Schlenk, Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.28, pp.4642-4648, 2010.

J. M. Hows, Comparison of long-term outcomes after allogeneic hematopoietic stem cell transplantation from matched sibling and unrelated donors, Bone Marrow Transplant, vol.38, pp.799-805, 2006.

J. Versluis, Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1, Blood Adv, vol.1, pp.477-485, 2017.

S. J. Lee, High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation, Blood, vol.110, pp.4576-4583, 2007.

N. Bejanyan, H. Haddad, and C. Brunstein, Alternative Donor Transplantation for Acute Myeloid Leukemia, J. Clin. Med, vol.4, pp.1240-1268, 2015.

R. Peffault-de-latour, Similar overall survival using sibling, unrelated donor, and cord blood grafts after reduced-intensity conditioning for older patients with acute myelogenous leukemia, Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant, vol.19, pp.1355-1360, 2013.

M. Eapen, Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis, Lancet Oncol, vol.11, pp.653-660, 2010.

R. Devillier, Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation, Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant, vol.20, pp.1560-1565, 2014.

J. R. Passweg, Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report, Bone Marrow Transplant, vol.52, pp.811-817, 2017.

Y. Wang, Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study, Blood, vol.125, pp.3956-3962, 2015.

S. O. Ciurea, Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia, Blood, vol.126, pp.1033-1040, 2015.

S. M. Davies, N. K. Ramsay, and D. J. Weisdorf, Feasibility and timing of unrelated donor identification for patients with ALL, Bone Marrow Transplant, vol.17, pp.737-740, 1996.

C. J. Lee, Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: A position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, Haematologica, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01633849

I. Yakoub-agha, Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.24, pp.5695-5702, 2006.

A. M. Raiola, Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts, Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant, vol.20, pp.1573-1579, 2014.

S. M. Davies, N. K. Ramsay, and D. J. Weisdorf, Feasibility and timing of unrelated donor identification for patients with ALL, Bone Marrow Transplant, vol.17, pp.737-740, 1996.

A. Ruggeri, Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia, Leukemia, vol.29, pp.1891-1900, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02007180

J. R. Passweg, Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants, Bone Marrow Transplant, vol.50, pp.476-482, 2015.

E. Kaplan and P. Meier, Nonparametric estimation for incomplete observations, J. Am. Stat. Assoc, pp.457-481, 1958.

G. Robert and J. , A Class of K-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk, The Annals of Statistics, pp.1141-1154, 1988.

M. Kohl, M. Plischke, K. Leffondré, and G. Heinze, PSHREG: a SAS macro for proportional and nonproportional subdistribution hazards regression, Comput. Methods Programs Biomed, vol.118, pp.218-233, 2015.

J. P. Fine and R. J. Gray, A Proportional Hazards Model for the Subdistribution of a Competing Risk, J. Am. Stat. Assoc, vol.94, pp.496-509, 1999.

D. R. Cox, Regression Models and Life-Tables, J. R. Stat. Soc. Ser. B Methodol, vol.34, pp.187-220, 1972.

P. M. Grambsch and T. M. Therneau, Proportional hazards tests and diagnostics based on weighted residuals, Biometrika, vol.81, pp.515-526, 1994.

N. Kekre, Impact of HLA-Mismatch in Unrelated Donor Hematopoietic Stem Cell Transplantation: A Meta-Analysis, Am. J. Hematol, vol.91, pp.551-555, 2016.

, En l'absence de donneur génoidentique ou compatible en HLA (Human Leukocyte Antigen) 10/10, une allogreffe reste possible grâce à 3 types de donneurs alternatifs: non apparenté 9/10, apparenté haploidentique ou sang de cordon, L'allogreffe de cellules souches hématopoïétiques est le seul traitement potentiellement curateur des leucémies aiguës myéloïdes (LAM)

, La survie globale post-inscription, la survie globale postgreffe et la mortalité toxique ont été évaluées par analyse multivariée en ajustant sur différents facteurs. La survie globale à 18 mois post-inscription et celle à 12 mois post-greffe ne sont pas significativement différentes selon le type de donneur. De même, la mortalité liée au traitement à 12 mois postgreffe n'est pas significativement différente après ajustement. Il existe une corrélation entre un délai inscription-greffe court et une meilleure survie ou une moindre mortalité, Cette étude rétrospective de registre, multicentrique, inclut 1302 adultes atteints de LAM allogreffés entre 2012 et 2016 avec un donneur non apparenté 10/10 (n=803), 9/10 (n=219), du sang placentaire (n=153) ou un donneur apparenté haploidentique (n=127)

. Mots-clés, Allogreffe de cellules souches hématopoïétiques, leucémie aiguë myéloïde, donneurs alternatifs, survie globale, délai inscription-greffe